Geron Corporation (NASDAQ:GERN) Experiences Heavier than Usual Trading Volume

Brunilde Fioravanti
Novembre 14, 2017

As of the latest earnings report the EPS was $-0.18 with 159.23M shares now outstanding.

2,889K shares changed hands on Monday. The company had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.40 million. During the same period in the previous year, the company posted ($0.02) earnings per share. analysts predict that Geron Corporation will post -0.17 EPS for the current year. Trading volume was up 113.64% over the stocks average daily volume. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement.

A number of research firms have recently weighed in on GERN. Finally, Stifel Nicolaus reaffirmed a "hold" rating and set a $2.50 price objective on shares of Geron Corporation in a research note on Friday, November 3rd. November 3 investment analysts at Needham & Company LLC maintained a "Hold" rating on the company. BidaskClub downgraded shares of Geron Corporation from a "hold" rating to a "sell" rating in a research report on Saturday, August 5th. The company now has an average rating of "Buy" and an average target price of $5.00. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company's stock worth $133,000 after acquiring an additional 17,877 shares in the last quarter.

Geron Corporation (GERN) has risen 4.28% since then.

According to analysts Geron Corporation (NASDAQ:GERN)'s minimum EPS for the current quarter is at $-0.05 and can go high up to $-0.04.

COPYRIGHT VIOLATION NOTICE: "Favorable Media Coverage Somewhat Unlikely to Affect Geron Corporation (GERN) Stock Price" was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another publication, it was illegally copied and reposted in violation of USA and worldwide trademark & copyright laws. TFS Capital LLC bought a new stake in Geron Corp. during the second quarter valued at approximately $145,000. IHT Wealth Management LLC bought a new position in shares of Geron Corporation in the second quarter worth about $122,000. Janney Montgomery Scott LLC boosted its stake in Geron 97.0% in the second quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 5,669 shares in the last quarter. Bank of America Corp DE now owns 65,403 shares of the biopharmaceutical company's stock worth $148,000 after buying an additional 13,698 shares during the period.

Geron Corporation (Geron), launched on November 28, 1990, is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. The Company is engaged in the development of therapeutic products for oncology.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE